Revenue, Revenue Recognized from Collaboration Agreements (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue Recognition [Abstract]
Total revenue from sale of therapies	$ 238,735	$ 140,687	$ 4,078
Collaboration revenue	10,693	33,674	32,406
Total revenue	249,428	174,361	36,484
GSK [Member]
Revenue Recognition [Abstract]
Collaboration revenue	0	0	8,385
Eli Lilly [Member]
Revenue Recognition [Abstract]
Collaboration revenue	0	9,205	0
Genentech [Member]
Revenue Recognition [Abstract]
Collaboration revenue	10,693	24,469	24,021
Product Revenue [Member]
Revenue Recognition [Abstract]
Total revenue from sale of therapies	238,735	130,013	0
Pre-Product Revenue [Member]
Revenue Recognition [Abstract]
Total revenue from sale of therapies	$ 0	$ 10,674	$ 4,078